Yale University

Running trials

• Recruiting

  Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

  NCT07605416· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

  NCT07578116· Phase 3· SWOG Cancer Research Network· Source

• Not yet recruiting

  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  NCT07881432· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Enrolling by invitation

  Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease

  NCT07356232· James Lewis· Source

• Not yet recruiting

  ThumpThump Pilot Study

  NCT07865247· Yale University· Source

• Recruiting

  Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes

  NCT07864168· Medtronic MiniMed, Inc.· Source

• Not yet recruiting

  Theoretically Informed Behavioral Intervention

  NCT06580184· Yale University· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy

  NCT07723963· Phase 2/3· Jazz Pharmaceuticals· Source

• Recruiting

  A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

  NCT07362082· Yale University· Source

• Recruiting

  Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.

  NCT07465718· Phase 3· Orphalan· Source

• Recruiting

  A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  NCT07794579· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

  NCT07214376· Pulnovo Medical, Inc.· Source

• Recruiting

  Rash & Diarrhea Prophylaxis With Capivasertib

  NCT07426822· Phase 2· Maryam Lustberg· Source

• Not yet recruiting

  Sac-TMT for Active TNBC Brain Metastases

  NCT07458113· Phase 2· Yale University· Source

• Recruiting

  Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

  NCT07216391· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

  NCT07610369· Phase 2· Yale University· Source

• Not yet recruiting

  Improving the Quality of Care for Asthma Patients at Risk of Exacerbations

  NCT06596512· Brigham and Women's Hospital· Source

• Recruiting

  Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

  NCT07215910· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Statins to Prevent Cancer Associated Blood Clots

  NCT07303816· Phase 4· Brigham and Women's Hospital· Source

• Recruiting

  Multi-Site Trial of Tirzepatide for Smoking Cessation

  NCT07602699· Phase 2· University of Southern California· Source

• Active, not recruiting

  Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life

  NCT07376655· Yale University· Source

• Recruiting

  RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry

  NCT07136363· University of Texas Southwestern Medical Center· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· AbbVie· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus

  NCT07142252· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Recruiting

  Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder

  NCT07029529· Phase 2· Yale University· Source

• Recruiting

  CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

  NCT07172256· Phase 2· Yale University· Source

• Enrolling by invitation

  LDART for Alcohol Use Disorder

  NCT07221383· Yale University· Source

• Enrolling by invitation

  LDART for Stimulant Use Disorder

  NCT07221396· Yale University· Source

• Recruiting

  A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer

  NCT07524855· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

  NCT07235917· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

  NCT07061574· Phase 1/2· City of Hope Medical Center· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· NRG Oncology· Source

• Recruiting

  Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

  NCT07360314· Phase 1· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  NCT07412756· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Digital Mindfulness for Young Adults With Type 1 Diabetes

  NCT07062887· Yale University· Source

• Recruiting

  INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

  NCT07224321· Phase 2· Mannkind Corporation· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Medtronic MiniMed, Inc.· Source

• Recruiting

  A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  NCT06968845· Phase 2· Rein Therapeutics· Source

• Recruiting

  Investigation of Lymph Node Biology in Kidney Cancer

  NCT07038733· Yale University· Source

• Active, not recruiting

  Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

  NCT07281014· Phase 4· Yale University· Source

• Recruiting

  Iadademstat + SBRT With Atezo in ES-SCLC

  NCT07113691· Phase 1· Yale University· Source

• Recruiting

  Home-based Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for IBS Pain

  NCT06847360· Yale University· Source

• Recruiting

  A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

  NCT07226427· Phase 1· Stemline Therapeutics, Inc.· Source

Showing 50 of 525.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers30 recruiting
• Lung cancer22 recruiting
• Colorectal cancer13 recruiting
• Ovarian cancer12 recruiting
• Acute myeloid leukaemia11 recruiting
• Heart failure10 recruiting
• Pancreatic cancer10 recruiting
• Type 1 diabetes10 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Multiple myeloma8 recruiting
• Type 2 diabetes8 recruiting
• Head and neck cancer7 recruiting
• Kidney cancer7 recruiting
• Metastatic breast cancer7 recruiting
• Myelodysplastic syndromes7 recruiting
• Alzheimer disease6 recruiting
• Gastric and oesophageal cancer6 recruiting
• HIV6 recruiting
• Prostate cancer6 recruiting
• Sarcoma6 recruiting
• Stroke6 recruiting
• Triple-negative breast cancer6 recruiting
• Amyloidosis5 recruiting
• Chronic kidney disease5 recruiting
• Crohn's disease5 recruiting
• Diffuse large B-cell lymphoma5 recruiting
• Endometrial cancer5 recruiting
• Melanoma5 recruiting
• Obesity5 recruiting
• High blood pressure4 recruiting
• Idiopathic pulmonary fibrosis4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Bladder cancer3 recruiting
• Chronic myeloid leukaemia3 recruiting
• Coronary artery disease3 recruiting
• Deep vein thrombosis and pulmonary embolism3 recruiting
• Depression3 recruiting
• Epilepsy3 recruiting
• Liver and biliary tract cancer3 recruiting
• Neuroendocrine tumours3 recruiting
• Parkinson disease3 recruiting
• Ulcerative colitis3 recruiting
• Asthma2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Down syndrome2 recruiting
• Glioblastoma2 recruiting
• Insomnia2 recruiting
• Mantle cell lymphoma2 recruiting
• Meningioma2 recruiting
• Mild cognitive impairment2 recruiting
• Multiple sclerosis2 recruiting
• Neuroblastoma2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Wilson disease2 recruiting
• Aortic aneurysm1 recruiting
• Autism1 recruiting
• Bipolar disorder1 recruiting
• Brain aneurysm1 recruiting
• Brain metastases1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Dystonia1 recruiting
• Fabry disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Female infertility1 recruiting
• Frontotemporal dementia1 recruiting
• Gaucher disease1 recruiting
• Hearing loss1 recruiting
• Hodgkin lymphoma1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Irritable bowel syndrome1 recruiting
• Liver cirrhosis1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Mitochondrial disease1 recruiting
• Neurofibromatosis type 11 recruiting
• Obstructive sleep apnoea1 recruiting
• Peripheral artery disease1 recruiting
• Polycystic kidney disease1 recruiting
• Pompe disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting
• Sjögren's disease1 recruiting
• Thyroid cancer1 recruiting
• Tourette syndrome1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

  NCT06973291· Phase 3· Takeda· Source

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· PDS Biotechnology Corp.· Source

• Completed

  NE3107 in Adults With Neurological Symptoms of Long COVID

  NCT06847191· Phase 2· BioVie Inc.· Source

• Completed

  Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

  NCT06865989· Insulet Corporation· Source

• Completed

  The Protrieve PROTECTOR Study

  NCT06495996· Inari Medical· Source

• Completed

  Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

  NCT06593600· Phase 2· Regeneron Pharmaceuticals· Source

• Withdrawn

  Withings Devices Follow-up Study - Hypertension

  NCT06692413· Withings· Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Phase 3· Vanderbilt University Medical Center· Source

• Completed

  Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

  NCT06377930· Phase 2· Rapport Therapeutics Inc.· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Terminated

  A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot

  NCT05966740· Boehringer Ingelheim· Source

• Completed

  Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use

  NCT06027840· Phase 1· Yale University· Source

• Recruiting

  RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

  NCT06121297· Phase 1/2· Cabaletta Bio· Source

• Withdrawn

  Neuroimmune Mechanisms in Obesity

  NCT05553405· Phase 1· Yale University· Source

• Completed

  EMPOWER AUD Pivotal Trial

  NCT05948605· Theranova, L.L.C.· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

  NCT06131437· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  The PEERLESS II Study

  NCT06055920· Inari Medical· Source

• Terminated

  Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

  NCT06068868· Phase 1· AbbVie· Source

• Terminated

  STOP-T1D Low-Dose (ATG)

  NCT04291703· Phase 2· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• Completed

  Tka Assay for CDK4/6i

  NCT06572800· Yale University· Source

• Recruiting

  A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  NCT06270706· Phase 1· Pliant Therapeutics, Inc.· Source

• Terminated

  PArtial REbreathing for Migraine With Aura 1

  NCT05546385· Rehaler· Source

• Completed

  Teplizumab in Pediatric Stage 2 Type 1 Diabetes

  NCT05757713· Phase 4· Sanofi· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex

  NCT05864846· Phase 4· Jazz Pharmaceuticals· Source

• Completed

  Real World Evidence Study in Subjects With Wilson's Disease

  NCT05783687· Orphalan· Source

• Completed

  Janus Kinase Inhibition in Sarcoidosis

  NCT05696795· Phase 2· Yale University· Source

• Completed

  The LEARN Study for CVD Prevention

  NCT05242952· Yale University· Source

• Completed

  A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers

  NCT05790681· Phase 1· Novo Nordisk A/S· Source

• Completed

  A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

  NCT05668091· Phase 2· Harlan M Krumholz· Source

• Completed

  WHOOP Abnormal Rhythm Notification

  NCT05809362· Yale University· Source

• Completed

  A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

  NCT05804383· Phase 1· Allyx Therapeutics· Source

• Completed

  FlowTriever2 Pulmonary Embolectomy Clinical Study

  NCT05560763· Inari Medical· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

  NCT05600426· Phase 3· Boston Children's Hospital· Source

• Recruiting

  PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

  NCT05313165· LimFlow, Inc.· Source

• Recruiting

  VIBRANT: VIB4920 for Active Lupus Nephritis

  NCT05201469· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  Evaluating the Safety and Efficacy of the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 PE for Treatment of Acute Pulmonary Embolism

  NCT05318092· Angiodynamics, Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

  NCT05374564· Phase 1· Yale University· Source

• Completed

  Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection

  NCT05010577· Phase 1/2· BiomX, Inc.· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· PTC Therapeutics· Source

• Completed

  Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

  NCT05325294· Medtronic MiniMed, Inc.· Source

• Completed

  FREEZE-AFIB Post-Market Study

  NCT05089877· AtriCure, Inc.· Source

• Completed

  SV2A Density Cannabis Use Disorder

  NCT05472818· Early phase 1· Yale University· Source

• Completed

  A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

  NCT05388474· Theratechnologies· Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Phase 2· Novartis Pharmaceuticals· Source

Showing 50 of 203.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke503 works · 12 trials
• HIV319 works · 13 trials
• Obesity306 works · 14 trials
• Heart failure299 works · 17 trials
• Lung cancer289 works · 68 trials
• Alzheimer disease275 works · 23 trials
• Type 2 diabetes178 works · 17 trials
• Schizophrenia152 works · 3 trials
• Atrial fibrillation113 works · 4 trials
• Prostate cancer108 works · 31 trials
• Liver and biliary tract cancer108 works · 20 trials
• Deep vein thrombosis and pulmonary embolism102 works · 11 trials
• Colorectal cancer102 works · 33 trials
• Melanoma102 works · 20 trials
• Epilepsy98 works · 6 trials
• Parkinson disease93 works · 4 trials
• Chronic kidney disease93 works · 8 trials
• Tuberculosis84 works · 1 trial
• Kidney cancer83 works · 28 trials
• Depression77 works · 5 trials
• Coronary artery disease76 works · 6 trials
• Psoriasis73 works · 4 trials
• Fatty liver disease (MASLD/MASH)71 works · 1 trial
• Autism71 works · 3 trials
• Asthma66 works · 3 trials
• Type 1 diabetes65 works · 21 trials
• Bipolar disorder59 works · 1 trial
• Ovarian cancer58 works · 28 trials
• Gastric and oesophageal cancer57 works · 10 trials
• Insomnia56 works · 2 trials